M
Mike Cinque
Researcher at Pfizer
Publications - 1
Citations - 146
Mike Cinque is an academic researcher from Pfizer. The author has contributed to research in topics: Drug resistance & Antigen. The author has an hindex of 1, co-authored 1 publications receiving 102 citations.
Papers
More filters
Journal ArticleDOI
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments
Frank Loganzo,Xingzhi Tan,Matthew Sung,Guixian Jin,Jeremy S. Myers,Eugene Melamud,Fang Wang,Veronica Diesl,Maximillian T. Follettie,Sylvia Musto,My-Hanh Lam,William T. Hu,Manoj Charati,Kiran Khandke,Kenny Sung Kyoo Kim,Mike Cinque,Judy Lucas,Edmund I. Graziani,Andreas Maderna,Christopher J. O’Donnell,Kim Arndt,Hans-Peter Gerber +21 more
TL;DR: In this article, a trastuzumab-maytansinoid ADC (TM-ADC) was applied to breast cancer cell lines, and the authors found that the ADC-resistant cells, 361-TM and JIMT1-TM, were characterized by cytotoxicity, proteomic, transcriptional and other profiling.